Physiological Effect: Decreased GI Motility

Drugs with Physiological Effect: Decreased GI Motility

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xeris	GVOKE VIALDX	glucagon	SOLUTION;INTRAVENOUS	212097-006	Mar 14, 2025		DISCN	Yes	No
Xeris	GVOKE PFS	glucagon	SOLUTION;SUBCUTANEOUS	212097-001	Sep 10, 2019		DISCN	Yes	No	9,649,364		Y
Xeris	GVOKE PFS	glucagon	SOLUTION;SUBCUTANEOUS	212097-001	Sep 10, 2019		DISCN	Yes	No	11,590,205		Y
Xeris	GVOKE PFS	glucagon	SOLUTION;SUBCUTANEOUS	212097-002	Sep 10, 2019		RX	Yes	Yes	9,649,364		Y
Xeris	GVOKE PFS	glucagon	SOLUTION;SUBCUTANEOUS	212097-002	Sep 10, 2019		RX	Yes	Yes	11,590,205		Y

Market dynamics and patent landscape for drugs that decrease GI motility

Last updated: July 6, 2026

Executive summary

Drugs with the physiological effect “decreased GI motility” span multiple therapeutic categories, including opioid analgesics (constipation), anticholinergics, 5-HT3 antagonists, somatostatin analogs, bile-acid modulators, and peripherally acting mu-opioid receptor antagonists (PAMORAs) used to reverse opioid-induced constipation. Patent estates differ sharply by class: opioid and anticholinergic core patents are largely expired or near-expiry, while newer constipation-focused pipelines concentrate in (1) PAMORAs with improved dosing/route profiles and (2) next-generation formulations (OTC switches, extended-release, combination products) that extend exclusivity through formulation and method-of-use claims. The most active “exclusivity risk” windows sit in constipation brands with frequent ANDA/Paragraph IV filings and in countries where granted secondary patents extend market control beyond primary API patents.

This landscape is best read as a set of class-specific battlegrounds rather than one unified patent universe, because “decreased GI motility” is a pharmacodynamic outcome shared by drugs with distinct molecular mechanisms and regulatory indications. The sections below map market drivers, patent strategies, regulatory exclusivity, and likely generic/biosimilar risk across the major drug families that produce reduced GI motility.

What drugs decrease GI motility and how do they segment by mechanism?

Featured snippet answer: The main mechanisms that reduce GI motility are opioid receptor activation (slows transit and increases sphincter tone), muscarinic antagonism (reduces smooth muscle contractility), serotonin 5-HT3 antagonism (modulates enteric signaling), somatostatin receptor activation (dampens secretions and motility), and bile-acid signaling effects (variable on formulation and target). In constipation programs, the dominant “IP extension” strategy targets peripherally acting reversal or improved constipation control.

Opioids that slow gut transit (constipation as a labeled and off-label outcome)

• Mechanism: activation of mu-opioid receptors in the enteric nervous system and GI smooth muscle
• Market linkage: chronic pain, oncology supportive care, and palliative care drive utilization
• Patent pattern: API composition and early use patents largely expired in many markets; later claims focus on extended-release matrices, abuse-deterrent or abuse-resistant technologies, fixed-dose combinations, and specific dosing regimens.

Anticholinergics (GI spasm and motility reduction)

• Mechanism: muscarinic receptor antagonism reduces GI smooth muscle activity
• Patent pattern: many anticholinergic actives have longstanding expiries; market differentiation often rests on formulation, salts, combination products, and therapeutic niche claims.

5-HT3 antagonists (nausea and GI functional modulation)

• Mechanism: blocks 5-HT3 receptors to influence enteric reflexes
• Patent pattern: older generation agents have mostly shifted to off-patent; newer programs and combinations focus on dosing regimens and patient subsets.

Somatostatin analogs (secretory and motility suppression)

• Mechanism: reduces GI secretions and motility through somatostatin receptor pathways
• Patent pattern: biologic/biosimilar dynamics apply to some agents; small-molecule somatostatin receptor modulators follow ANDA logic but depend on whether the product is approved as a small molecule.

Constipation-directed reversal: PAMORAs (peripherally acting mu-opioid receptor antagonists)

• Mechanism: antagonize peripheral mu-opioid receptors to reverse opioid-induced constipation without reversing analgesia
• Competitive nuance: PAMORAs are frequently long-lived in the constipation franchise because they target a defined, reimbursed indication and attract multiple generic entrants over time.

How do market dynamics differ between opioid-induced constipation and other GI motility-reduction indications?

Featured snippet answer: Opioid-induced constipation (OIC) behaves like a chronic, reimbursement-linked market with higher switching costs, while antispasmodic and nausea-linked indications behave more episodically, which reduces the economic urgency for “must-launch-on-time” generic competition.

OIC and chronic constipation market mechanics

• Drivers
  • Opioid prevalence in pain and oncology care
  • Chronic dosing and ongoing prescribing by primary care, pain clinics, and gastroenterology
  • Reimbursement pathways and formulary positioning for chronic symptom management
• Switching dynamics
  • Once an agent is on formulary, payer and prescriber inertia tends to delay switching to new entrants
  • However, clinician reliance on “class familiarity” can make Paragraph IV generics commercially viable once barriers fall

Anticholinergic and antinausea market mechanics

• Drivers
  • Symptom episodicity
  • Generic substitution in pharmacy settings when patents expire
• Switching dynamics
  • Higher likelihood of rapid price competition once product-level exclusivities end
  • Less sustained dedicated pipelines unless a new delivery platform or combination is created

What patents protect drugs that decrease GI motility, and where is the estate strongest?

Featured snippet answer: For most GI motility-decreasing drugs, the strongest enforceable patent layers concentrate in secondary patents covering formulation, dosing, route of administration, and method-of-use, not in the earliest composition-of-matter claims. For OIC and constipation, the “estate strength” often depends on whether the brand has multiple granted formulation or method-of-use patents with coordinated timing across major markets.

Patent estate layers that commonly matter

1. Composition of matter (primary API)
   • Often expired or near-expiry for older drug families
2. Method-of-use claims
   • Typically cover specific indications, patient populations, or dosing regimens for GI motility reduction-related outcomes
3. Formulation and delivery system patents
   • Extended-release matrices
   • Abuse-deterrent technologies (for opioids)
   • Specialty coatings to control GI release
4. Combination patents
   • Fixed-dose combinations with laxatives or anti-spasmodics
   • Rationalized dosing schedules

Where to expect the “hold-up” patents in constipation

• PAMORAs and related constipation brands frequently accumulate:
  • dosing interval patents (e.g., once-daily regimens)
  • specific dose strength compositions
  • particulate or solid-state forms
  • enteric or controlled-release coatings
  • method-of-use claims tethered to opioid-induced constipation endpoints

When do GI motility-decreasing drugs lose exclusivity, and how do exclusivity types change launch timing?

Featured snippet answer: Market “loss of exclusivity” typically comes in three waves: (1) composition-of-matter expiry, (2) regulatory exclusivities (New Chemical Entity, New Clinical Investigation, pediatric exclusivities), and (3) product-specific secondary patent expiry tied to formulation or method-of-use.

Regulatory exclusivity mechanics that shift timing

• NCE exclusivity: blocks FDA approval for generic products that rely on the brand’s safety and efficacy package
• 505(b)(2) and switching pathways: can reset exclusivity if clinical data are newly submitted
• Pediatric exclusivity: extends certain eligible exclusivities by 6 months when pediatric requirements are fulfilled

Patent-to-ANDA timing logic (Paragraph IV window)

• Hatch-Waxman litigation strategy:
  • If a brand has multiple Orange Book-listed patents covering formulation and method-of-use, generic applicants often face multiple infringement theories and leverage multiple “carve-out” strategies
• For constipation brands, the most common friction points are:
  • whether a formulation falls within a claimed particle size range or solid-state form
  • whether the generic’s dosing regimen meets the method-of-use claim limitations

What is the Orange Book status of major GI motility-decreasing and OIC drugs?

Featured snippet answer: The Orange Book status is product-specific and must be read at the ingredient and dosage-form level; the key practical point is that many GI motility-decreasing brands maintain Orange Book listings that extend beyond primary API expiry due to formulation or method-of-use patents.

How to interpret Orange Book listings for this PD class

• Ingredients with multiple dosage forms (tablets, liquids, extended-release) frequently carry separate patent lists per dosage
• If an ANDA lists “same as” dosage form and strengths, the same listed patents typically control the immediate risk of Paragraph IV entry
• If the ANDA uses a different delivery system, the generic’s freedom-to-operate depends on whether secondary claims cover functional characteristics that are shared across delivery technologies

How strong is the patent estate for constipation and motility suppression drugs?

Featured snippet answer: Estate strength is highest where brands have:

• multiple granted Orange Book patents,
• late-expiring formulation/method-of-use claims,
• active enforcement history against ANDAs,
• and a product set with tight claim boundaries that require “design-around” rather than simple generic substitution.

Typical strength signals for constipation franchises

• Multiple expiring patent families close together but across distinct claim categories
• Consistent litigation activity over a multi-year span
• Settlement agreements that preserve brand economics by delaying generic launches

Which companies are challenging patents for GI motility-decreasing drugs?

Featured snippet answer: Generic challengers in GI motility reduction and OIC markets typically include large ANDA players and constipation specialists, with Paragraph IV filings clustering when multiple Orange Book patents expire in a narrow window.

Filing and litigation patterns

• Early filers tend to:
  • challenge the easiest-to-design patents (often formulation claims first)
  • maintain an infringement posture that attempts non-infringement or invalidity arguments on later-stage method claims
• Settlement-driven dynamics:
  • Brands frequently settle to secure a delayed launch and avoid worst-case injunction risk

What patent litigation affects the GI motility-decreasing market most?

Featured snippet answer: Litigation impacts market entry timing most when brands have both (1) granted secondary patents and (2) a litigation history showing consistent infringement theories that are hard for ANDA applicants to negate.

Common litigation issues in this space

• Formulation infringement:
  • solid-state form identity, polymorph inclusion, excipient composition, and dissolution profiles
• Method-of-use infringement:
  • whether patient indication in the ANDA label triggers induced infringement
• Carve-out label strategies:
  • generic applicants often seek narrower labeling to reduce method claim exposure

What formulations are protected, and how do design-arounds work for motility-decreasing drugs?

Featured snippet answer: The most design-around-prone claims cover controlled release behavior, particle size distributions, dissolution windows, and dosing regimens. Generic firms can sometimes avoid infringement by altering release kinetics, solid-state form, or dosing schedule, but that can raise CMC and clinical bridging costs.

Formulation claim categories that matter in practice

• Extended-release matrices
• Solid-state forms:
  • polymorph, hydrate/solvate form
  • amorphous vs crystalline
• Coatings:
  • enteric and controlled release coatings
• Combination products:
  • ratios and release ordering of multiple actives

How does opioid-induced constipation therapy compare on patent estate versus non-opioid motility reducers?

Featured snippet answer: OIC therapies (particularly PAMORAs) show more crowded and more resilient patent estates than non-opioid motility reducers because the OIC indication is tightly defined, reimbursed, and treated as a chronic-care category that supports multiple secondary patent layers.

Side-by-side commercial implications

• OIC:
  • chronic dosing supports durable revenues
  • brands justify additional formulation and method-of-use IP investment
  • generic entrants face label and regimen constraints
• Non-opioid:
  • episodic usage supports faster price competition after primary expiry
  • fewer method-of-use constraints in many labels

What generic entry risks exist for drugs that decrease GI motility?

Featured snippet answer: Generic entry risks rise when (1) Orange Book-listed secondary patents expire and (2) no later-expiring method-of-use claims remain enforceable for the generic’s intended label and dosage form.

Risk factors by claim type

• Lower risk for brands
  • If secondary patents are late-expiring and broadly worded
• Higher risk for brands
  • If patent lists are sparse
  • If enforcement history is weak
  • If generic applicants can use different release profiles and avoid method-of-use triggers

What biosimilar risk exists for motility-decreasing drugs?

Featured snippet answer: Biosimilar risk is relevant only for biologics (and some receptor-targeting biologics) that decrease GI motility. For small molecules and most anticholinergics, biosimilar risk is not applicable; the risk becomes ANDA-based generic competition.

Biosimilar-sensitive segments

• Somatostatin-analog biologics
• Any peptide-based motility-modulating agents approved via biologics pathways

What is the global geographic exposure for GI motility-decreasing drugs?

Featured snippet answer: Exposure varies mainly by:

• whether secondary patents are filed and granted in each jurisdiction,
• and whether enforcement and settlements occurred in parallel in major markets (US, EU, UK, Canada, Japan).

Practical geographic pattern

• US and EU often carry the densest Orange Book-style patent layers
• Japan and Canada may have enforceable secondary patents that extend control
• Settlement outcomes can be jurisdiction-specific, so the “first wave” of generic entry may not generalize globally

Key Takeaways

• “Decreased GI motility” is a pharmacodynamic endpoint shared across multiple drug mechanisms; patent strategy and exclusivity timelines vary by class.
• Patent estates for constipation and opioid-induced constipation therapies tend to be strongest in secondary patents covering formulation and method-of-use, which slows generic launch until late expiry or settlement.
• Market dynamics for OIC are chronic and reimbursement-linked, increasing the commercial value of late-stage IP and settlement-based launch delays.
• Generic entry risk is highest when Orange Book-listed secondary patents expire and when the generic label and dosing avoid method-of-use triggers.
• Biosimilar risk applies only to biologic-derived motility reducers; small-molecule and anticholinergic classes follow ANDA competition pathways.

FAQs

1) Which constipation drugs have the most Orange Book-listed patents for formulation and method-of-use?

2) How do Paragraph IV carve-outs on indication and dosage affect infringement risk for OIC therapies?

3) What formulation attributes most often determine whether a generic design-around avoids controlled-release patent claims?

4) Do pediatric exclusivities materially delay generic entry for GI motility-decreasing brands?

5) How do extended-release and abuse-deterrent technologies change the patent litigation landscape for opioid-linked constipation?

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-07-06).